For the independent thinker.
Industry to bear the cost of expensive new medicines?
In a ground-breaking government-industry PPRS scheme, both sides have agreed the cash level of prescription sales over the next five years.
Built into the scheme is a quarterly rebate to be paid back to the NHS because of the forecasted difference between anticipated sales of medicines and the NHS drugs budget.
But if the spend is higher than anticipated, the rebate will be adjusted upwards – so in effect the industry has agreed to take the weight of the additional expenditure, whatever that is. This should remove the object of cost from CCGs and other payers as the industry (as a whole) will pay back all overspend over the agreed five-year sales plan.
All salesforces should be notified – the relative cost of medicines is no longer an issue, it’s whether it’s the right medicine for the right patient at the right time.
So is this a green light for the NHS to spend on the best medicines?
About PharmaTimes Magazine
PharmaTimes Magazine is the ONLY UK publication designed for all levels
of industry management – offering original, news-driven features on all
aspects of the sector, from sales and marketing to clinical, regulatory,
advertising, PR and human resources. A comprehensive round up of global
industry and National Health Service news, as well the latest
developments in the agency and recruitment arenas, will also help you
stay ahead of the pack.
average net circulation of 12,470.
PharmaTimes Online News Archive offers unique access to past issues of PharmaTimes Magazine and news elert stories.
©PharmaTimes Magazine 2013. All rights reserved. Material prepared by PharmaTimes Magazine is prohibited for use by third parties and publishers without permission.